Min-wei Li1, Wei Hou, Jian-er Wo, Ke-zhou Liu. 1. Institute of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. limw@zju.edu.cn
Abstract
OBJECTIVES: To investigate the relationship between HBV (hepatitis B virus) polymerase gene 180 and 204 sites mutation and lamivudine resistance. METHODS: One hundred forty-one patients with lamivudine resistance after lamivudine treatment and 60 chronic hepatitis B patients without lamivudine treatment were enrolled in this study. The serum HBV DNA mutation was analyzed by sequence detection via polymerase chain reaction (PCR). The sequences of the same patient were analyzed before and after lamivudine treatment. RESULTS: One hundred and nine lamivudine resistance patients had HBV YMDD (tyrosine-methionine-aspartate-aspartate) mutation. Among them, 45 patients had rtL180M/M204V mutation (41.28%), 28 patients had rtL180M/M204I mutation (25.70%) and 36 patients had rtM204I mutation (33.02%). There were 6 patients with rtL180M mutation in 32 lamivudine resistance patients. Sixty chronic hepatitis patients without lamivudine treatment had no mutations. CONCLUSIONS: HBV mutations, which play an important role in lamivudine resistance usually locate at polymerase gene 204 site; 180 site mutation was also observed in these patients. Evaluation of the anti-virus therapy by surveillance of the two sites mutations is of importance.
OBJECTIVES: To investigate the relationship between HBV (hepatitis B virus) polymerase gene 180 and 204 sites mutation and lamivudine resistance. METHODS: One hundred forty-one patients with lamivudine resistance after lamivudine treatment and 60 chronic hepatitis Bpatients without lamivudine treatment were enrolled in this study. The serum HBV DNA mutation was analyzed by sequence detection via polymerase chain reaction (PCR). The sequences of the same patient were analyzed before and after lamivudine treatment. RESULTS: One hundred and nine lamivudine resistance patients had HBV YMDD (tyrosine-methionine-aspartate-aspartate) mutation. Among them, 45 patients had rtL180M/M204V mutation (41.28%), 28 patients had rtL180M/M204I mutation (25.70%) and 36 patients had rtM204I mutation (33.02%). There were 6 patients with rtL180M mutation in 32 lamivudine resistance patients. Sixty chronic hepatitispatients without lamivudine treatment had no mutations. CONCLUSIONS:HBV mutations, which play an important role in lamivudine resistance usually locate at polymerase gene 204 site; 180 site mutation was also observed in these patients. Evaluation of the anti-virus therapy by surveillance of the two sites mutations is of importance.
Authors: L J Stuyver; S A Locarnini; A Lok; D D Richman; W F Carman; J L Dienstag; R F Schinazi Journal: Hepatology Date: 2001-03 Impact factor: 17.425
Authors: K S Gutfreund; M Williams; R George; V G Bain; M M Ma; E M Yoshida; J P Villeneuve; K P Fischer; D L Tyrrel Journal: J Hepatol Date: 2000-09 Impact factor: 25.083
Authors: J L Dienstag; E R Schiff; T L Wright; R P Perrillo; H W Hann; Z Goodman; L Crowther; L D Condreay; M Woessner; M Rubin; N A Brown Journal: N Engl J Med Date: 1999-10-21 Impact factor: 91.245
Authors: Jong Chul Kim; Hye Young Lee; Ah Ram Lee; Mehrangiz Dezhbord; Da Rae Lee; Seong Ho Kim; Juhee Won; Soree Park; Na Yeon Kim; Jae Jin Shin; Sang Gyune Kim; Young Seok Kim; Jeong-Ju Yoo; Kyun-Hwan Kim Journal: Biomedicines Date: 2022-01-26